Ukuqwashisa, Ukwelashwa
Inyanga kaMashi yinyanga yokuqwashisa ngomdlavuza we-colorectal
Mashi 2023: Ngo-2020, cishe izigameko eziyizigidi ezi-2 zomdlavuza we-colorectal zizotholakala emhlabeni wonke, okuwenza kube uhlobo lwesithathu oluvame kakhulu lomdlavuza. Kuyimbangela yesibili ehamba phambili yokufa okuhlobene nomdlavuza, okubalelwa cishe esigidini esisodwa.
Ukwelashwa kwe-CAR - T Cell, China, India, Ukwelashwa, USA
Isu elisha le-immunotherapy ye-myeloma eminingi
Emashumini eminyaka amuva nje, ukwelashwa komdlavuza osuselwa ku-monoclonal anti-antibody kusungulwe njengenye yezindlela eziphumelela kakhulu zokwelapha izicubu eziqinile nomdlavuza wegazi. Njengoba igama lisho, ama-antibody monoclonal (mAbs) yi-antibo ..
China, Cost, Gastric, Gastroenterology, India, Israel, Singapore, Isisu, Ukwelashwa, USA
Ukuqhubeka nokuthatha le mithi kungaphindaphinda ingozi yomdlavuza wesisu
Ucwaningo olushicilelwe ku- "Intestine" luveze ukuthi ukusetshenziswa kwesikhathi eside kwama-proton pump inhibitors kuzophinda kabili ingozi yomdlavuza wesisu. I-Proton pump inhibitors yisigaba semithi esetshenziselwa ukwelapha i-gastric acid reflux. , Ukusetshenziswa okuqhubekayo kwe thi ..
China, India, Israel, URamucirumab, Singapore, Ukwelashwa, USA
URamucirumab ekwelapheni umdlavuza wesisu
Ngokwezibalo, iziguli ezinomdlavuza wesisu elashwa e-United States, eYurophu naseJapan zivame ukunconywa ukuthi zisebenzise i-ramucirumab ngokuhlangana nezinye izidakamizwa ukwelapha umdlavuza wesisu I-US Food and Drug Administra ..
immunotherapy, Isibindi, Singapore, Ukwelashwa
ISingapore iqale yamukela i-T cell engineering immunotherapy yomdlavuza wesibindi
Agasti 19, 2018: Inkampani yase-Singapore biotechnology i-Lion TCR Pte. Ltd. yagunyazwa yi-Singapore Health Sciences Authority (HSA), futhi umkhiqizo wayo (i-LioCyx ™) ingasetshenziselwa isigaba I/II socwaningo lomtholampilo lokwelapha.
Isibindi, Ukwelashwa
Umuthi omusha ekwelapheni umdlavuza wesibindi
Ithimba labacwaningi e-Cancer Research Institute (CSI) le-National University of Singapore lisungule umuthi oyinhlayiya we-peptide obizwa nge-FFW ongavimbela ukuthuthukiswa kwe-hepatocellular carcinoma (HCC) noma isibindi esiyinhloko ca ..
China, India, Israel, Isibindi, Therapy, Ukwelashwa, USA
Ukufa ngenxa yomdlavuza wesibindi sekuphindwe kabili kusukela ngo-1990
Kule minyaka engamashumi amabili edlule, isibalo sabantu abashona ngenxa yomdlavuza wesibindi senyuke ngo-80%, okube ngesinye sezimbangela ezikhula ngokushesha zokufa komdlavuza emhlabeni jikelele. Ngokwe "Global Burden of Disease Study", abantu abangu-830,000 bafa.
ukuphumelela, China, India, Israel, Isibindi, Singapore, Ukwelashwa, USA
Ukuqhamuka komdlavuza wesibindi - U-Vitamin C ukhetha ukubulala iseli lomdlavuza wesibindi
Ekupheleni kuka-2015, ucwaningo lwesayensi lwathi imithamo ephezulu kavithamini C (olingana namawolintshi angama-300) ingabulala ngempumelelo amangqamuzana omdlavuza wamakholoni athwala ukuguquka komzimba okuvamile (KRAS neBRAF) .NgoMashi 2017, "Canc ..
Ukwelashwa kwamaseli, China, India, Ukwelashwa kwe-NK Cell, Ukwelashwa, USA
NK Cell immunotherapy - Isikhathi esisha ekwelapheni umdlavuza
Iyini i-NK-cell therapy? Izigidigidi zamangqamuzana ziphindaphindeka kumuntu nsuku zonke. Ngaphansi kwethonya lama-carcinogens (ukubhema, imisebe ye-ionizing, i-Helicobacter pylori, njll.), amaseli angaba ngu-500,000 kuya ku-1 million angashintsha ngesikhathi sokuphendula.
India, Ukwelashwa
Amathemba okwelashwa kwe-CAR T-Cell ukwelapha umdlavuza ajabulisa kakhulu
What is CAR T-Cell therapy ? CAR T-Cell therapy, whose full name is Chimeric Antigen Receptor T-Cell Immunotherapy,. This is a new type of cell therapy that has been used for many years, but has only been improved and used clinic..